Resolution of cutaneous leishmaniasis after acute eczema due to intralesional meglumine antimoniate.

Abstract

We report a case of a 42 year-old female, who came to a leishmaniasis reference center in Rio de Janeiro, Brazil, presenting a cutaneous leishmaniasis lesion in the right forearm. Treatment with low-dose intramuscular meglumine antimoniate (MA) (5 mg Sb5+/kg/day) was initiated, with improvement after 28 days, although with the development of generalized eczema. After 87 days, the lesion worsened. Patient refused treatment with amphotericin B. MA was then infiltrated in the lesion, in two sessions, resulting in local eczema, with bullae formation; however, twenty days after, both the ulcer and eczema receded. Intralesional administration of MA should be used carefully when previous cutaneous hypersensitivity is detected.

• Authors: Erica de Camargo Ferreira e Vasconcellos, Maria Inês Fernandes Pimentel, Cláudia Maria Valete-Rosalino, Maria de Fátima Madeira, Armando de Oliveira Schubach
• Journal: Revista do Instituto de Medicina Tropical de Sao Paulo (Rev Inst Med Trop Sao Paulo) 2014 Jul-Aug Vol. 56 Issue 4 Pg. 361-2 ISSN: 1678-9946 [Electronic] Brazil
• PMID: 25076440 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antiprotozoal Agents
• Organometallic Compounds
• Meglumine
• Meglumine Antimoniate

Topics

• Adult
• Antiprotozoal Agents (administration & dosage, adverse effects)
• Drug Eruptions (drug therapy)
• Eczema (chemically induced, drug therapy)
• Female
• Humans
• Injections, Intralesional
• Injections, Intramuscular
• Leishmaniasis, Cutaneous (drug therapy)
• Meglumine (administration & dosage, adverse effects)
• Meglumine Antimoniate
• Organometallic Compounds (administration & dosage, adverse effects)